Research Title: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration.
Sponsor: Regeneron Pharmaceuticals
Principal Investigator: Michael Jacobson, M.D.
Description: The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.
Start Date: September 2015
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CRC
Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084